This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


NB Health Laboratory Co.Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery
Drug discovery support/Contract service

last update:2016/3/3
Profile

Delegates :
KIYOSHI TAKAYAMA


Incorporated :
July  7 , 2006

Paid in Capital :
59 Million yen  

Employees :
9 人

Address :
#110 W4-1-16, N21, KITA-KU, SAPPORO HOKKAIDO
〒0010021

TEL/FAX :
+81-11-708-7156 / +81-11-700-3009

URL:
http://www.nbhl.co.jp/  

Attachment :

Mission/Background :
NBHL is committed to discovering First-In-Class medicines for the unmet medical needs with the sophisticated drug discovery platforms(Monoclonal Antibody for GPCR and Small compound screening ). We are looking for the pharmaceutical partners to develop our projects regarding lung inflammation and CNS. We also propose the technology alliance for functional mAbs targeting at GPCR, using our proprietary technology platform.

Technology & Business
1.The antigen formats and the antibody screening methods fit the development of functional GPCR mAbs with the proprietary technologies.
2.The most crucial point of the platform is that the GPCR expressed in conformationally stable form in vivo is used as antigen, in stead of synthesized peptides corresponding to extracellular domain predicted in silico.
3.The platform have track records of success including GPCRs for lipid mediators, chemokines, a peptide and an amine.
4.Two of the functional GPCR mAbs are currently under development as therapeutic mAbs.
Products & Service
Products & Service Name
Stage
Outline
Milestone
Technology Platform for Functional Therapeutic GPCR mAbs
Discovery
Technology Platform fit the development of functional GPCR mAbs with the proprietary technolo
Conclusion of on-going partnership agreements
Small compounds for sleeping disorder with dementia
Discovery
The compounds, selective kinase inhibitor, augment NREM sleep.
CMC and Preclinical












Highlights
1) Establishment of a research collaboration with major Japanese basic research laboratories
2) Minister of Economy, Trade and Industry (METI) supports our technology platform for functional mAbs targeting at GPCR financially.

Hot news

Alliance strategy
1.NBHL produces humanized functional GPCR mAbs for pharmaceutical companies according to their specifications.
2.NBHL generates and optimizes the antibodies, whereas the partner is mainly responsible for pre-clinical and clinical development.
3.Development-dependent milestone payments and royalties on product sales are standard components of these agreements, whereas various options for alliance are available.


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.